A Multicenter Pilot Study of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma

NCT03143270 EARLY_PHASE1 ACTIVE_NOT_RECRUITING

The purpose of the study is to find out the effects of using nivolumab with Drug Eluting Bead Transarterial Chemoembolization (deb-TACE) in the treatment of liver cancer.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	EARLY_PHASE1
Status	ACTIVE_NOT_RECRUITING
Enrolment	20
Start date	2017-04-28
Completion	2027-04

Conditions

• Liver Cancer

Interventions

• Drug Eluting Bead Transarterial Chemoembolization
• Nivolumab

Primary outcomes

• Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 — 12 months
  The percentage of subjects who experience toxicity at each schedule will be calculated. Frequencies of toxicities will be tabulated according to the NCI CTCAE scale (version 4.03).

Countries

United States